The vector of anti-EBV T cell receptor (TCR) is constructed for the engineering of T cell to target EBV. The T cells are genetically modified through transduction with a retroviral vector expressing EBV-specific T cell receptor. And the vector product was designed for the treatment of infectious mononucleosis, Burkitt's lymphoma, Hodgkin's lymphoma,gastric cancer,nasopharyngeal carcinoma, multiple sclerosis, and lymphomatoid granulomatosis.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|TCR-L018||Human anti-LMP2 (TYPVLEEMF) T Cell Receptor, pMX-IRES-GFP|
|TCR-L057||Human anti-LMP2 (CLGGLLTMV) T Cell Receptor, pMP71|
|TCR-L017||Human anti-LMP2 (SSCSSCPLSK) T Cell Receptor, pMP71|
|TCR-C110Z||Human anti-LMP2 T cell receptor (PL5.05), pCDTCR1|
|TCR-L056Z||Human anti-LMP2 (CLGGLLMW) T cell receptor, pCDTCR1|
|TCR-C112Z||Murinized anti-LMP2 T cell receptor, pCDTCR1|
|TCR-C108Z||Human anti-LMP2 T cell receptor (8), pCDTCR1|
|TCR-C109Z||Human anti-LMP2 T cell receptor (NB20), pCDTCR1|
|TCR-L056||Human anti-LMP2 (CLGGLLWT) T Cell Receptor, pSFG|
|TCR-L055Z||Human anti-LMP2 (CLGGLLWT) T cell receptor, pCDTCR1|
|TCR-L015||Human anti-LMP2 (FLRGRAYGL) T Cell Receptor, pMP71|
|TCR-C111Z||Human anti-LMP2 T cell receptor (PL5.04), pCDTCR1|
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved